drugset / Trial / NCT06149676
A Novel Probiotic-antibiotic Combination to Prevent Recurrent Urinary Tract Infections
RandomizedParallel-groupOpen-labelPrevention
Summary
Patients with recurrent UTI were randomized to receive either the probiotic Sacchromyces Boulardii at enrollment, and the intracellularly active Ciprofloxacin with their first UTI episode after enrollment, or they received standard of care treatment.
Timeline
- Start
- 2022-02-02
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Saccharomyces boulardii | Other / unclassified | 250 mg | — |
| Background | Ciprofloxacin | Small molecule | 20 mg/kg | — |